SAB Biotherapeutics, Inc. (SABS) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 114.7K | 0 | 263.14K | 944.58K | 305.01K | 1.27M | 85.52K |
| Revenue Growth % | - | -100% | - | -100% | -100% | -62.4% | -100% | 207.7% | 62.55% | -85.88% | -64.7% | -98.65% |
| Cost of Goods Sold | 752.67K | 763.3K | 765.47K | 822K | 0 | 785.71K | 966.86K | 1.02M | 1.98M | 944.4K | 985.45K | 892.27K |
| COGS % of Revenue | - | - | - | - | - | 685.03% | - | 388.39% | 210.12% | 309.63% | 77.78% | 1043.37% |
| Gross Profit | -752.67K | -763.3K | -765.47K | -822K | 0 | -671.01K | -966.86K | -758.86K | -1.04M | -639K | 281.92K | -806.75K |
| Gross Margin % | - | - | - | - | - | -585.03% | - | -288.39% | -110.12% | -209.5% | 22.25% | -943.37% |
| Gross Profit Growth % | - | -13.75% | 20.83% | -8.32% | 100% | -5.01% | -442.96% | 5.94% | -204.08% | -151.64% | -89.48% | 63.89% |
| Operating Expenses | 19.25M | 15.01M | 11.91M | 8.91M | 10.77M | 9.34M | 10.34M | 9.44M | 10.35M | 18.23M | 5.6M | 5.67M |
| OpEx % of Revenue | - | - | - | - | - | 8141.23% | - | 3588.56% | 1095.78% | 5978.27% | 442.37% | 6630.03% |
| Selling, General & Admin | 5.87M | 5.04M | 3.71M | 2.74M | 3.11M | 1.71M | 2.51M | 2.64M | 2.23M | 14.88M | 2.57M | 2.03M |
| SG&A % of Revenue | - | - | - | - | - | 1489.01% | - | 1004.28% | 235.67% | 4878.84% | 202.92% | 2375.21% |
| Research & Development | 13.38M | 10.73M | 8.95M | 7M | 7.66M | 7.63M | 7.83M | 6.8M | 8.12M | 4.3M | 4.02M | 3.64M |
| R&D % of Revenue | - | - | - | - | - | 6652.22% | - | 2584.28% | 860.11% | 1408.8% | 317.28% | 4254.82% |
| Other Operating Expenses | 0 | -763.3K | -743.76K | -822K | 0 | 0 | 0 | 0 | 0 | -943.62K | -986.16K | 0 |
| Operating Income | -20M | -15.77M | -12.68M | -9.73M | -10.77M | -10.01M | -11.31M | -10.2M | -11.39M | -18.87M | -5.32M | -6.48M |
| Operating Margin % | - | - | - | - | - | -8726.26% | - | -3876.95% | -1205.9% | -6187.97% | -420.13% | -7573.4% |
| Operating Income Growth % | -85.64% | -57.56% | -12.11% | 4.6% | 5.43% | 46.97% | -112.46% | -57.52% | -53.89% | -140.13% | 31.82% | 1.01% |
| EBITDA | -19.25M | -15.01M | -11.91M | -8.91M | -9.99M | -9.22M | -10.34M | -9.18M | -9.41M | -17.93M | -4.34M | -5.58M |
| EBITDA Margin % | - | - | - | - | - | -8041.23% | - | -3488.56% | -995.78% | -5878.35% | -342.35% | -6530.03% |
| EBITDA Growth % | -92.57% | -62.71% | -15.19% | 2.94% | -6.25% | 48.56% | -138.44% | -64.38% | -45.18% | -158.48% | 37.11% | 3.61% |
| D&A (Non-Cash Add-back) | 752.67K | 763.3K | 765.47K | 822K | 778.3K | 785.71K | 966.86K | 1.02M | 1.98M | 944.4K | 985.45K | 892.27K |
| EBIT | -20M | -16.8M | 45.49M | -10.05M | -5.13M | -11.32M | -10.27M | -7.24M | -4.95M | -22.78M | -5.03M | -6.81M |
| Net Interest Income | 984.45K | 637.28K | 611.94K | -50.78K | -7.07K | 65.5K | 199.14K | 281.44K | 421.52K | 406.17K | -55.34K | -46.75K |
| Interest Income | 1.05M | 700.74K | 655.23K | 13.56K | 62.5K | 136.37K | 277.17K | 374.56K | 497.89K | 484.05K | 14.36K | 28.57K |
| Interest Expense | 62.74K | 63.46K | 43.29K | 64.34K | 69.56K | 70.88K | 78.04K | 93.12K | 76.37K | 77.88K | 69.7K | 75.32K |
| Other Income/Expense | 1.13M | -1.09M | 58.12M | -382.21K | 5.58M | -1.39M | 959.96K | 2.87M | 6.36M | -3.98M | 220.6K | -404.27K |
| Pretax Income | -18.87M | -16.86M | 45.45M | -10.11M | -5.2M | -11.39M | -10.35M | -7.34M | -5.03M | -22.86M | -5.1M | -6.88M |
| Pretax Margin % | - | - | - | - | - | -9934.52% | - | -2787.69% | -532.06% | -7493.83% | -402.68% | -8046.13% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -18.87M | -16.86M | 45.45M | -10.11M | -5.2M | -11.39M | -10.35M | -7.34M | -5.03M | -22.86M | -5.1M | -6.88M |
| Net Margin % | - | - | - | - | - | -9934.52% | - | -2787.69% | -532.06% | -7493.83% | -402.68% | -8046.13% |
| Net Income Growth % | -263.09% | -47.97% | 539.11% | -37.88% | -3.4% | 50.15% | -102.85% | -6.61% | 31.66% | -190.26% | 27.9% | -44.07% |
| Net Income (Continuing) | -18.87M | -16.86M | 45.45M | -10.11M | -5.2M | -11.39M | -10.35M | -7.34M | -5.03M | -22.86M | -5.1M | -6.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.35 | -0.81 | -0.21 | -1.09 | -0.56 | -1.23 | -1.12 | -0.79 | -0.54 | -3.86 | -0.97 | -1.36 |
| EPS Growth % | 37.5% | 34.15% | 81.25% | -37.97% | -3.7% | 68.13% | -15.46% | 41.91% | 63.01% | -147.44% | 39.38% | -22.52% |
| EPS (Basic) | -0.35 | -2.39 | 4.26 | -1.09 | -0.56 | -1.23 | -1.12 | -0.79 | -0.54 | -3.86 | -0.97 | -1.36 |
| Diluted Shares Outstanding | 53.56M | 61.34M | 77.86M | 9.29M | 9.29M | 9.26M | 9.26M | 9.26M | 9.24M | 5.93M | 5.24M | 5.04M |
| Basic Shares Outstanding | 53.56M | 19.31M | 10.66M | 9.29M | 9.29M | 9.26M | 9.26M | 9.26M | 9.24M | 5.93M | 5.24M | 5.04M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |